Enzalutamide, also known as MDV3100, is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. In August 2012, the United States (U.S.) Food and Drug Administration (FDA) approved enzalutamide for the treatment of castration-resistant prostate cancer.
Androgen Receptor Inhibitors Related Products:
Chlormadinone acetate; Bicalutamide; Apalutamide; Galeterone; Cyproterone acetate; AZD-3514; Spironolactone; ARV-110; Darolutamide; Megestrol Acetate; Clascoterone; RU-58841